XML 43 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)
In Thousands, unless otherwise specified
 9 Months Ended
Oct. 31, 2012
Oct. 31, 2011
Cash flows from operating activities    
Net income $ 48,805 $ 44,600
Adjustments to reconcile net income to net cash used by operating activities, net of assets and liabilities acquired:    
Depreciation and amortization 6,964 5,251
Equity based compensation 4,493 3,616
Tax benefit from exercise/vesting of equity awards 1,261 746
Deferred financing charges 280 365
Equity loss in joint venture 706 812
Gain on sale of joint venture interest (185)  
Changes in operating assets and liabilities:    
Accounts receivable, net (193,181) (229,746)
Inventories (44,005) (68,166)
Income taxes, net 21,358 24,031
Prepaid expenses and other current assets (1,742) 648
Other assets, net (3,791) 103
Accounts payable, accrued expenses and other liabilities 18,911 (4,459)
Net cash used in operating activities (140,259) (222,199)
Cash flows from investing activities    
Acquisition of Vilebrequin, net of cash acquired (80,252)  
Proceeds from (investment in) equity of joint venture, net 1,898 (3,350)
Capital expenditures (6,992) (12,937)
Net cash used in investing activities (85,346) (16,287)
Cash flows from financing activities    
Proceeds from notes payable, net 235,042 245,058
Noncontrolling interest investment, net 2,309  
Proceeds from exercise of equity awards 1,182 516
Stock repurchase   (2,929)
Excess tax benefit from exercise/vesting of equity awards 1,720 1,957
Net cash provided by financing activities 240,253 244,602
Foreign currency translation adjustments 3,553 (78)
Net increase / (decrease) in cash and cash equivalents 14,986 6,038
Cash and cash equivalents at beginning of period 24,660 10,045
Cash and cash equivalents at end of period 39,646 16,083
Cash paid during the period for:    
Interest 7,794 3,364
Income taxes $ 4,867 $ 1,134